Early recovery of oxygen kinetics after submaximal exercise test predicts functional capacity in patients with chronic heart failure.

Abstract:

BACKGROUND:Oxygen (O2) uptake at peak exercise (VO2 peak) is an objective measurement of functional capacity in patients with chronic heart failure (CHF). The significance of recovery O2 kinetics parameters in predicting exercise capacity, and the parameters of submaximal exercise testing have not been thoroughly examined. METHODS AND RESULTS:Thirty-six patients (mean age = 48+/-14 years) with CHF and New York Heart Association functional class I, II, or III, and eight healthy volunteers (mean age = 39+/-13 years) were studied with maximal and submaximal cardiopulmonary exercise testing (CPET). The first degree slope of O2 uptake decay during early recovery from maximal (VO2/t-slope), and submaximal exercise (VO2/t-slope)(sub), were calculated, along with VO2 half-time (T(1/2)VO2). Patients with CHF had a longer recovery of O2 uptake after exercise than healthy volunteers, expressed by a lower VO2/t-slope (0.616+/-0.317 vs. 0.956+/-0.347 l min(-1) min(-1), P=0.029) and greater T(1/2)VO2 (1.28+/-0.30 vs. 1.05+/-0.15 min, P = 0.005). VO2/t-slope correlated with the VO2 peak (r = 0.84, P<0.001), anaerobic threshold (r = 0.79, P<0.001), and T(1/2)VO2, a previously established estimate of recovery O2 kinetics (r = -0.59, P<0.001). (VO2/t-slope)(sub) was highly correlated with VO2/t-slope after maximal exercise (r=0.87, P<0.001), with the VO2 peak (r=0.87, P<0.001) and with T(1/2)VO2 after maximal exercise (r=-0.62, P<0.001). VO2/t-slope after maximal and submaximal exercise was reduced in patients with severe exercise intolerance (F=9.3, P<0.001 and F=12.8, P<0.001, respectively). CONCLUSIONS:Early recovery O2 kinetics parameters after maximal and submaximal exercise correlate closely with established indices of exercise capacity in patients with CHF and in healthy volunteers. These findings support the use of early recovery O2 kinetics after submaximal exercise testing as an index of functional capacity in patients with CHF.

journal_name

Eur J Heart Fail

authors

Nanas S,Nanas J,Kassiotis C,Nikolaou C,Tsagalou E,Sakellariou D,Terovitis I,Papazachou O,Drakos S,Papamichalopoulos A,Roussos C

doi

10.1016/s1388-9842(01)00187-8

keywords:

subject

Has Abstract

pub_date

2001-12-01 00:00:00

pages

685-92

issue

6

eissn

1388-9842

issn

1879-0844

pii

S1388-9842(01)00187-8

journal_volume

3

pub_type

杂志文章
  • The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects.

    abstract:AIMS:Liver X receptors (LXRs) transcriptionally regulate inflammation, metabolism, and immunity. Synthetic LXR agonists have been evaluated for their efficacy in the cardiovascular system; however, they elicit prolipogenic side effects which substantially limit their therapeutic use. AZ876 is a novel high-affinity LXR ...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1002/ejhf.243

    authors: Cannon MV,Yu H,Candido WM,Dokter MM,Lindstedt EL,Silljé HH,van Gilst WH,de Boer RA

    更新日期:2015-03-01 00:00:00

  • The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial.

    abstract:BACKGROUND:Crataegus preparations have been used for centuries especially in Europe. To date, no proper data on their efficacy and safety as an add-on-treatment are available. Therefore a large morbidity/mortality trial was performed. AIM:To investigate the efficacy and safety of an add-on treatment with Crataegus ext...

    journal_title:European journal of heart failure

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.ejheart.2008.10.004

    authors: Holubarsch CJ,Colucci WS,Meinertz T,Gaus W,Tendera M,Survival and Prognosis: Investigation of Crataegus Extract WS 1442 in CHF (SPICE) trial study group.

    更新日期:2008-12-01 00:00:00

  • Primary proteasome inhibition results in cardiac dysfunction.

    abstract:AIMS:The proteasome prevents the intracellular accumulation of proteins and its impairment can lead to structural and functional alterations, as noted for the coronary vasculature in a previous study. Utilizing the same model, this study was designed to test the hypothesis that chronic proteasome inhibition (PSI) also ...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1093/eurjhf/hft034

    authors: Herrmann J,Wohlert C,Saguner AM,Flores A,Nesbitt LL,Chade A,Lerman LO,Lerman A

    更新日期:2013-06-01 00:00:00

  • Evolving concepts in dilated cardiomyopathy.

    abstract::Dilated cardiomyopathy (DCM) represents a particular aetiology of systolic heart failure that frequently has a genetic background and usually affects young patients with few co-morbidities. The prognosis of DCM has improved substantially during the last decades due to more accurate aetiological characterization, the r...

    journal_title:European journal of heart failure

    pub_type: 杂志文章,评审

    doi:10.1002/ejhf.1103

    authors: Merlo M,Cannatà A,Gobbo M,Stolfo D,Elliott PM,Sinagra G

    更新日期:2018-02-01 00:00:00

  • Dietary sodium modulation of aldosterone activation and renal function during the progression of experimental heart failure.

    abstract:AIMS:Aldosterone activation is central to the sodium–fluid retention that marks the progression of heart failure (HF). The actions of dietary sodium restriction, a mainstay in HF management, on cardiorenal and neuroendocrine adaptations during the progression of HF are poorly understood. The study aim was to assess the...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1002/ejhf.212

    authors: Miller WL,Borgeson DD,Grantham JA,Luchner A,Redfield MM,Burnett JC Jr

    更新日期:2015-02-01 00:00:00

  • Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial.

    abstract:AIMS:To investigate the prognostic value of autonomic variables in patients with symptomatic chronic heart failure (HF) treated according to current recommendations. METHODS AND RESULTS:We analysed 24 h time-domain [standard deviation of all normal-to-normal RR intervals (SDNN)], frequency-domain [very low frequency a...

    journal_title:European journal of heart failure

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1093/eurjhf/hfs126

    authors: La Rovere MT,Pinna GD,Maestri R,Barlera S,Bernardinangeli M,Veniani M,Nicolosi GL,Marchioli R,Tavazzi L,GISSI-HF Investigators.

    更新日期:2012-12-01 00:00:00

  • Low-dose nitroglycerin improves microcirculation in hospitalized patients with acute heart failure.

    abstract:AIMS:Impaired tissue perfusion is often observed in patients with acute heart failure. We tested whether low-dose nitroglycerin (NTG) improves microcirculatory perfusion in patients admitted for acute heart failure. METHODS AND RESULTS:In 20 acute heart failure patients, NTG was given as intravenous infusion at a fixe...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1093/eurjhf/hfp021

    authors: den Uil CA,Lagrand WK,Spronk PE,van der Ent M,Jewbali LS,Brugts JJ,Ince C,Simoons ML

    更新日期:2009-04-01 00:00:00

  • Increased Rho kinase activity in congestive heart failure.

    abstract:AIMS:Rho kinases (ROCKs) are the best characterized effectors of the small G-protein RhoA, and play a role in enhanced vasoconstriction in animal models of congestive heart failure (CHF). This study examined if ROCK activity is increased in CHF and how it is associated with the outcome in CHF. METHODS AND RESULTS:Pati...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1093/eurjhf/hfs068

    authors: Dong M,Liao JK,Fang F,Lee AP,Yan BP,Liu M,Yu CM

    更新日期:2012-09-01 00:00:00

  • Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.

    abstract:AIMS:Risk stratification in patients admitted with worsening heart failure (HF) is essential for tailoring therapy and counselling. Risk models are available but rarely used, in part because many require laboratory and imaging results that are not routinely available. Body temperature is associated with prognosis in ot...

    journal_title:European journal of heart failure

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1093/eurjhf/hft113

    authors: Payvar S,Spertus JA,Miller AB,Casscells SW,Pang PS,Zannad F,Swedberg K,Maggioni AP,Reid KJ,Gheorghiade M,Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators.

    更新日期:2013-12-01 00:00:00

  • Usefulness of bifocal pacing in patients with heart failure and intraventricular conduction delay.

    abstract:BACKGROUND:Bifocal pacing (BFP) has been proposed as a feasible alternative to cardiac resynchronization therapy. AIM:To evaluate BFP in patients with severe heart failure and significant intraventricular conduction delay and to compare it with biventricular pacing (BVP). METHODS:Echocardiographic examination includi...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1016/j.ejheart.2006.09.003

    authors: Bulava A,Lukl J

    更新日期:2007-03-01 00:00:00

  • Experience of commencing Carvedilol in elderly patients with heart failure in a routine outpatient clinic.

    abstract::Carvedilol has been shown to be beneficial for patients with heart failure, but it is not clear how it should be initiated in routine clinical practice, particularly in the elderly. This study is a retrospective review of 19 patients of age 80+/-4 years with heart failure, who had Carvedilol treatment initiated in a r...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1016/s1388-9842(00)00092-1

    authors: Owen A

    更新日期:2000-09-01 00:00:00

  • Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme.

    abstract:AIMS:Heart failure (HF) and chronic obstructive pulmonary disease are common partners. Bronchodilators are associated with adverse cardiovascular outcomes in patients with pulmonary disease. The outcome of patients with HF prescribed bronchodilators is poorly defined. METHODS AND RESULTS:The Candesartan in Heart failu...

    journal_title:European journal of heart failure

    pub_type: 杂志文章,随机对照试验

    doi:10.1093/eurjhf/hfq040

    authors: Hawkins NM,Wang D,Petrie MC,Pfeffer MA,Swedberg K,Granger CB,Yusuf S,Solomon SD,Ostergren J,Michelson EL,Pocock SJ,Maggioni AP,McMurray JJ,CHARM Investigators and Committees.

    更新日期:2010-06-01 00:00:00

  • Which patients with heart failure should receive specialist palliative care?

    abstract:AIMS:We investigated which patients with heart failure (HF) should receive specialist palliative care (SPC) by first creating a definition of need for SPC in patients hospitalised with HF using patient-reported outcome measures (PROMs) and then testing this definition using the outcome of days alive and out of hospital...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1002/ejhf.1240

    authors: Campbell RT,Petrie MC,Jackson CE,Jhund PS,Wright A,Gardner RS,Sonecki P,Pozzi A,McSkimming P,McConnachie A,Finlay F,Davidson P,Denvir MA,Johnson MJ,Hogg KJ,McMurray JJV

    更新日期:2018-09-01 00:00:00

  • Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy.

    abstract:AIMS:Chronic hypertension may cause left ventricular hypertrophy (LVH). The role of matrix metalloproteinases (MMPs), tissue inhibitors of matrix metalloproteinases (TIMPs), and tenascin-C (Tn-C) splice variants in concentric vs. eccentric left ventricular remodelling has not been investigated. METHODS AND RESULTS:Ser...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1093/eurjhf/hfp128

    authors: Franz M,Berndt A,Altendorf-Hofmann A,Fiedler N,Richter P,Schumm J,Fritzenwanger M,Figulla HR,Brehm BR

    更新日期:2009-11-01 00:00:00

  • Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications.

    abstract::Most treatments for chronic heart failure are effective both in preventing its onset and reducing its progression. However, statins prevent the development of heart failure, but they do not decrease morbidity and mortality in those with established heart failure. This apparent discordance cannot be explained by an eff...

    journal_title:European journal of heart failure

    pub_type: 杂志文章,评审

    doi:10.1002/ejhf.1183

    authors: Packer M

    更新日期:2018-07-01 00:00:00

  • Diagnosis and management of aortic valve stenosis in patients with heart failure.

    abstract::Aortic stenosis (AS) is the most frequent degenerative valvular heart disease in Western countries and its prevalence increases in parallel with the ageing process of the population. Heart failure (HF), defined by the presence of reduced left ventricular ejection fraction, may be present in up to a quarter of patients...

    journal_title:European journal of heart failure

    pub_type: 杂志文章,评审

    doi:10.1002/ejhf.466

    authors: Kamperidis V,Delgado V,van Mieghem NM,Kappetein AP,Leon MB,Bax JJ

    更新日期:2016-05-01 00:00:00

  • Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure.

    abstract::The ELITE-II, BEST and CHAMP Trials were reported for the first time at the American Heart Association in November 1999. These trials provide valuable new information to guide clinical practice in the management of heart failure and of myocardial infarction, although none mandate a major change from current clinical p...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1016/s1388-9842(00)00053-2

    authors: Witte K,Thackray S,Banerjee T,Clark AL,Cleland JG

    更新日期:2000-03-01 00:00:00

  • Cellular basis of uraemic cardiomyopathy: a role for erythropoietin?

    abstract::The use of erythropoietin (EPO) has revolutionized the treatment of anaemia associated with many conditions including chronic kidney disease (CKD). However, little is known of the cellular impact of EPO on the uraemic heart. The discovery that the EPO receptor (EPOR) is also expressed on non-haematopoietic cells inclu...

    journal_title:European journal of heart failure

    pub_type: 杂志文章,评审

    doi:10.1093/eurjhf/hfp093

    authors: Smith K,Semple D,Bhandari S,Seymour AM

    更新日期:2009-08-01 00:00:00

  • Improved angiogenic response in pig heart following ischaemic injury using human skeletal myoblast simultaneously expressing VEGF165 and angiopoietin-1.

    abstract:OBJECTIVE:To achieve angiogenic interaction between VEGF(165) and angiopoietin-1 (Ang-1) using a novel adenoviral bicistronic vector (Ad-Bic) encoding the two factors and delivered ex vivo using sex-mismatched human skeletal myoblasts. METHODS AND RESULTS:A myocardial infarction model was developed in 29 female pigs; ...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1016/j.ejheart.2006.04.008

    authors: Ye L,Haider HKh,Jiang S,Tan RS,Ge R,Law PK,Sim EK

    更新日期:2007-01-01 00:00:00

  • Left atrial volume predicts abnormal exercise left ventricular filling pressure.

    abstract:AIMS:Latent heart failure at rest can be observed in a number of patients upon exercise. Considering left atrial (LA) remodelling as the reflection of the cumulative effects of the LV filling pressure (FP) over time, our aim was to investigate whether the LA volume would predict abnormal exercise LVFP. METHODS AND RES...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1002/ejhf.131

    authors: Hammoudi N,Achkar M,Laveau F,Boubrit L,Djebbar M,Allali Y,Komajda M,Isnard R

    更新日期:2014-10-01 00:00:00

  • Increasing glucose levels and BMI predict future heart failure experience from the Reykjavík Study.

    abstract:BACKGROUND:Heart failure is common in diabetes and ischaemic heart disease is the most likely link. Still, it has been suggested that the relation extends beyond such disease. METHODS:7060 subjects with two or more visits in the Reykjavík Study were followed--during 30 years from 1967. All underwent oral glucose toler...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1016/j.ejheart.2007.07.017

    authors: Thrainsdottir IS,Aspelund T,Gudnason V,Malmberg K,Sigurdsson G,Thorgeirsson G,Hardarson T,Rydén L

    更新日期:2007-10-01 00:00:00

  • COMBAT--conventional versus multisite pacing for bradyarrhythmia therapy: rationale of a prospective randomized multicenter study.

    abstract::COMBAT is a prospective, multicenter, randomized, blinded clinical study, with crossover design. The main objective is the comparative evaluation of atrio-biventricular versus conventional atrioventricular stimulation (atrio and right ventricle) in patients with heart failure and bradycardia as the primary indication ...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1016/j.ejheart.2004.06.008

    authors: Martinelli M,Costa R,de Siqueira SF,Ramires JA

    更新日期:2005-03-02 00:00:00

  • C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study.

    abstract:BACKGROUND:High-sensitivity C-reactive protein (CRP) is an inflammatory marker that predicts coronary heart disease (CHD) and, in recent studies, incident heart failure (HF). Whether the association of inflammation with incident HF is explained by worse baseline left ventricular dysfunction or by underlying CHD is unkn...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1016/j.ejheart.2007.11.003

    authors: Williams ES,Shah SJ,Ali S,Na BY,Schiller NB,Whooley MA

    更新日期:2008-01-01 00:00:00

  • Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure.

    abstract:AIMS:Recent studies have shown that microRNAs (miRNAs), besides being potent regulators of gene expression, can additionally serve as circulating biomarkers of disease. The aim of this study is to determine if plasma miRNAs can be used as indicators of disease progression or therapeutic efficacy in hypertension-induced...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1093/eurjhf/hft018

    authors: Dickinson BA,Semus HM,Montgomery RL,Stack C,Latimer PA,Lewton SM,Lynch JM,Hullinger TG,Seto AG,van Rooij E

    更新日期:2013-06-01 00:00:00

  • Hemochromatosis mutations are not linked to dilated cardiomyopathy in Israeli patients.

    abstract:AIMS:Hemochromatosis is a condition in which iron loading impairs the function of many organs, including the heart. Congestive heart failure with left ventricular dilatation is commonly found in patients with hemochromatosis. Two missense mutations (C282Y and H63D) have been shown to be responsible for the majority of ...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1016/j.ejheart.2003.11.003

    authors: Goland S,Beilinson N,Kaftouri A,Shimoni S,Caspi A,Malnick SD

    更新日期:2004-08-01 00:00:00

  • Chronic heart failure is associated with vascular remodeling of the brachial artery.

    abstract:AIMS:Endothelial dysfunction has been shown to correlate with severity of congestive heart failure (CHF) and recent data suggest morphological changes of peripheral vasculature to be associated with the syndrome. We therefore investigated the hypothesis that vascular remodeling is associated with functional changes in ...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1016/j.ejheart.2004.04.008

    authors: Poelzl G,Frick M,Huegel H,Lackner B,Alber HF,Mair J,Herold M,Schwarzacher S,Pachinger O,Weidinger F

    更新日期:2005-01-01 00:00:00

  • Angiopoietin-1 for myocardial angiogenesis: a comparison between delivery strategies.

    abstract:UNLABELLED:We compare the effectiveness of direct adenoviral angiopoietin-1 (Ad-Ang-1) injection with transplantation of skeletal myoblasts (SkMs) over-expressing angiopoietin-1 (Ang-1) for angiogenic response and improvement of heart function in an experimental porcine model of myocardial infarction (MI). METHODS:Ad-...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1016/j.ejheart.2006.10.022

    authors: Ye L,Haider HKh,Jiang S,Tan RS,Toh WC,Ge R,Sim EK

    更新日期:2007-05-01 00:00:00

  • Reduced in vivo skeletal muscle oxygen consumption in patients with chronic heart failure--a study using Near Infrared Spectrophotometry (NIRS).

    abstract:AIM:We used Near Infrared Spectrophotometry (NIRS) during arterial occlusion to measure resting skeletal muscle oxygen consumption in chronic heart failure (CHF) patients and in age-matched healthy volunteers (HVs). METHODS:Fifteen CHF patients (ten males) and eleven HVs (six males) had echocardiographic evaluation fo...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1016/j.ejheart.2008.05.009

    authors: Abozguia K,Phan TT,Shivu GN,Maher AR,Ahmed I,Wagenmakers A,Frenneaux MP

    更新日期:2008-07-01 00:00:00

  • Is the diagnostic coding position of acute heart failure related to mortality? A report from the Euro Heart Failure Survey-1.

    abstract:AIMS:Most studies on acute heart failure (HF) exploring the relationship between admissions to hospital for HF and subsequent outcomes have focused only on HF coded as the primary diagnosis, but many other patients have admissions complicated by HF requiring attention. Failure to quantify the total hospital burden of H...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1002/ejhf.505

    authors: Shoaib A,Farag M,Nasir M,John J,Gupta S,Pellicori P,Antony R,Perveen R,Rigby A,Goode KM,Yassin A,Clark AL,Cleland JG

    更新日期:2016-05-01 00:00:00

  • N-terminal pro-brain natriuretic peptide from fresh urine for the biochemical detection of heart failure and left ventricular dysfunction.

    abstract:AIMS:Plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) is a strong biochemical marker of heart failure and left ventricular dysfunction (LVD). Due to renal arterio-venous clearance of NT-proBNP and the correlation of plasma concentrations with renal function, we hypothesized that NT-proBNP may have potential ...

    journal_title:European journal of heart failure

    pub_type: 杂志文章

    doi:10.1093/eurjhf/hfq016

    authors: Jungbauer CG,Buchner S,Birner C,Resch M,Heinicke N,Debl K,Buesing M,Biermeier D,Schmitz G,Riegger G,Luchner A

    更新日期:2010-04-01 00:00:00